Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~* Age 18-60~Exclusion Criteria:~* Primary psychiatric disease (DSM IV Axis I or WHO ICD-10 diagnostic classification).~* Present or former neurological diseases,~* Severe somatic disease~* Medication that can interfere with the test results.~* Doesn't speak Danish fluently or is severely, visually or hearing impaired.~* Information regarding former learning disabilities.~* Pregnancy at the time of the scanning~* Breast feeding~* MR-scanner incompatibility (metal in soft tissue)~* Alcohol or drug abuse~* Allergy to ingredients in used drugs~* Participation in experiments with radioactivity (\>10 mSv) within the last year or considerable work-related exposure to radioactivity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Sumatriptan (Type: EXPERIMENTAL): In the pilot study (an MR-only study) subjects will receive up to five doses of sumatriptan in the range of 10 ug/kg to 80 ug/kg. This allows us to establish a dose-response curve for each subject. Administration of sumatriptan in the pilot study will be spaced with approximately one week apart to avoid carry-over effects of the drug.~In the main study (a PET-MR study), the sumatriptan dose with the maximal effect size and minimum side effects will be used for all subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).